Tag: dosing
Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization
Vancouver, BC, Apr 3, 2024 - (ACN Newswire) - Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the private clinical-stage pharmaceutical company developing psilocybin treatment for alcohol use disorder...
Top News
Breaking News
NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient...
New EHR Integration Simplifies Provider Workflow for Patients Living With Diabetes
Tidepool announces new EHR integration tailored to accommodating health system-specific workflow requirements
PALO ALTO, Calif.–(BUSINESS WIRE)–#EHR–Tidepool, a software company committed to innovations in diabetes management,...
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension...
– Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Placebo-Adjusted Reduction of 24-Hour Mean Systolic Blood Pressure at Three Months of Treatment –
–...
Anebulo Pharmaceuticals Announces New CEO
Richie Cunningham announced as Chief Executive Officer and member of Anebulo’s board of directors
AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo”), a clinical-stage biopharmaceutical...
“LEQEMBI Intravenous Infusion” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
TOKYO and CAMBRIDGE, Mass., Sept 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated...
Metaverse Technology Market Size & Share | Industry Forecast – 2030 – CryptoInfoNet
Introducing Our Latest Metaverse Technology Market Research Report Unveiling In-Depth Analysis of Industry Trends, Growth, and Opportunities:The Metaverse Technology Market 2023-2030 | Research report...
Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease
Houston, TX, June 8, 2023 - (ACN Newswire) - Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic programs intended to...
Investing in Orbital Therapeutics
“The fact that proteins are not synthesized directly on genes demands the existence of an intermediate information carrier…which receives genetic information from the gene...
AAAS Panel Recaps: Improving Mental Health and Supporting Self-regulation with Technology
Mental well-being is essential to a happy life, and especially with the stresses of the pandemic heightening the mental health crisis plaguing the US...
5 Important Roles of a Clinical Research Organization
Clinical research is how new drugs and treatments are validated, tested, and improved. It’s a long and detailed process that involves testing drugs...
First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors
Dosing marks first time a computationally designed monoclonal antibody enters human trial in the U.S.
U.S. enrollment begins in North Carolina, with additional sites being...
MRI guidance reduces side effects of prostate cancer radiotherapy
Stereotactic body radiotherapy (SBRT) is an established treatment for prostate cancer. It involves delivering large...
Latest Intelligence
